×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GALT – galectin therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
03:11 am
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/18
08:07 am
galt
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting [Yahoo! Finance]
Medium
Report
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting [Yahoo! Finance]
11/18
08:00 am
galt
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Medium
Report
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
11/15
08:03 am
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Medium
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
11/14
08:12 am
galt
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update [Yahoo! Finance]
Medium
Report
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update [Yahoo! Finance]
11/14
08:00 am
galt
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
Medium
Report
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
11/13
12:08 am
galt
Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/15
08:00 am
galt
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Low
Report
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
08:00 am
GALT
galectin therapeutics inc.
BEAT
Report
-7.1%
galectin therapeutics inc.
8/13/2024
08:00 am
GALT
galectin therapeutics inc.
MISS
Report
8.2%
galectin therapeutics inc.
5/15/2024
08:00 am
GALT
galectin therapeutics inc.
MISS
Report
7.7%
galectin therapeutics inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
08:01 am
galt
Form 8-K GALECTIN THERAPEUTICS For: Nov 14
Medium
Report
Form 8-K GALECTIN THERAPEUTICS For: Nov 14
11/14
07:56 am
galt
Form 8-K GALECTIN THERAPEUTICS For: Nov 14
Medium
Report
Form 8-K GALECTIN THERAPEUTICS For: Nov 14
11/14
07:51 am
galt
Form 10-Q GALECTIN THERAPEUTICS For: Sep 30
Medium
Report
Form 10-Q GALECTIN THERAPEUTICS For: Sep 30
10/23
01:40 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Oct 23 Filed by: ELDRED KARY
Neutral
Report
Form 4 GALECTIN THERAPEUTICS For: Oct 23 Filed by: ELDRED KARY
10/17
04:04 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Oct 17 Filed by: FREEMAN KEVIN D
Low
Report
Form 4 GALECTIN THERAPEUTICS For: Oct 17 Filed by: FREEMAN KEVIN D
10/16
04:12 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Oct 16 Filed by: FREEMAN KEVIN D
Neutral
Report
Form 4 GALECTIN THERAPEUTICS For: Oct 16 Filed by: FREEMAN KEVIN D
10/4
04:10 pm
galt
Form 144 GALECTIN THERAPEUTICS Filed by: Boudes Pol F
Medium
Report
Form 144 GALECTIN THERAPEUTICS Filed by: Boudes Pol F
9/9
08:01 am
galt
Form 8-K GALECTIN THERAPEUTICS For: Sep 09
Medium
Report
Form 8-K GALECTIN THERAPEUTICS For: Sep 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/10
Form 4 GALECTIN THERAPEUTICS For: Feb 09 Filed by: LEWIS JOEL
11.8%
11/11 Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis 9.8%
8/9 Form S-3 GALECTIN THERAPEUTICS 7.8%
10/23 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. 6.7%
3/20 Form 4 GALECTIN THERAPEUTICS For: Mar 19 Filed by: FREEMAN KEVIN D 6.7%
2/20 Form 8-K GALECTIN THERAPEUTICS For: Feb 19 6.3%
3/16 Form 3 GALECTIN THERAPEUTICS For: Mar 02 Filed by: Boudes Pol F 4.8%
10/17 Form DEF 14A GALECTIN THERAPEUTICS For: Dec 04 3.6%
6/3 Form 4 GALECTIN THERAPEUTICS For: May 29 Filed by: Uihlein Richard E 3.6%
2/4 Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 2.8%
11/11 Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis 9.8%
8/9 Form S-3 GALECTIN THERAPEUTICS 7.8%
10/23 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. 6.7%
3/20 Form 4 GALECTIN THERAPEUTICS For: Mar 19 Filed by: FREEMAN KEVIN D 6.7%
2/20 Form 8-K GALECTIN THERAPEUTICS For: Feb 19 6.3%
3/16 Form 3 GALECTIN THERAPEUTICS For: Mar 02 Filed by: Boudes Pol F 4.8%
10/17 Form DEF 14A GALECTIN THERAPEUTICS For: Dec 04 3.6%
6/3 Form 4 GALECTIN THERAPEUTICS For: May 29 Filed by: Uihlein Richard E 3.6%
2/4 Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 2.8%
TOP News Decliners
3/16
Form 8-K GALECTIN THERAPEUTICS For: Mar 16
-17.0%
11/12 Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 -16.9%
4/30 Form 8-K GALECTIN THERAPEUTICS For: Apr 30 -9.0%
4/2 Galectin Therapeutics Update on the Impact of COVID-19 -6.1%
10/24 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
12/4 Form 8-K GALECTIN THERAPEUTICS For: Dec 04 -5.6%
8/13 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
8/9 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -4.8%
11/15 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -4.3%
7/25 Form 4 GALECTIN THERAPEUTICS For: Jul 15 Filed by: 10X Capital Management, LLC -4.1%
11/12 Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 -16.9%
4/30 Form 8-K GALECTIN THERAPEUTICS For: Apr 30 -9.0%
4/2 Galectin Therapeutics Update on the Impact of COVID-19 -6.1%
10/24 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
12/4 Form 8-K GALECTIN THERAPEUTICS For: Dec 04 -5.6%
8/13 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
8/9 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -4.8%
11/15 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -4.3%
7/25 Form 4 GALECTIN THERAPEUTICS For: Jul 15 Filed by: 10X Capital Management, LLC -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: